Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Nanoviricides Inc
(NY:
NNVC
)
1.730
UNCHANGED
Streaming Delayed Price
Updated: 8:00 PM EDT, Jun 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nanoviricides Inc
< Previous
1
2
3
4
5
6
Next >
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides
June 24, 2024
Via
ACCESSWIRE
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 20, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
June 20, 2024
Via
Benzinga
Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect
June 11, 2024
Via
ACCESSWIRE
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect
June 04, 2024
Via
ACCESSWIRE
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
May 29, 2024
Via
ACCESSWIRE
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model
June 20, 2024
Via
ACCESSWIRE
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 14, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
June 14, 2024
Via
Benzinga
Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure
May 20, 2024
Via
ACCESSWIRE
NanoViricides Has Filed its Quarterly Report
May 15, 2024
Via
ACCESSWIRE
A Novel Broad-Spectrum Antiviral with Activity Against RSV
May 14, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's Intraday Session
June 12, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
June 10, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
June 06, 2024
Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news affecting shares this morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
June 05, 2024
Via
Benzinga
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
May 08, 2024
Via
ACCESSWIRE
A Novel Broad-Spectrum Antiviral with Activity Against Influenza A
May 06, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's After-Market Session
June 04, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
June 03, 2024
Via
Benzinga
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results
May 29, 2024
Via
AB Newswire
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
May 23, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Intraday Session
May 16, 2024
Via
Benzinga
NNVC Stock Earnings: Nanoviricides Beats EPS for Q3 2024
May 15, 2024
NNVC stock results show that Nanoviricides beat analyst estimates for earnings per share the third quarter of 2024.
Via
InvestorPlace
NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City
May 10, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Monday's Intraday Session
May 06, 2024
Via
Benzinga
3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire
May 02, 2024
Discover three nanotech stocks poised for explosive growth in a booming market. Explore their potential for massive returns.
Via
InvestorPlace
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
April 30, 2024
Via
ACCESSWIRE
NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
February 15, 2024
Via
ACCESSWIRE
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics
February 01, 2024
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.